Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1.5%

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)’s share price was down 1.5% during mid-day trading on Wednesday . The stock traded as low as $0.90 and last traded at $0.90. Approximately 593,049 shares changed hands during trading, a decline of 39% from the average daily volume of 978,133 shares. The stock had previously closed at $0.91.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, May 6th.

Lineage Cell Therapeutics Stock Down 3.2 %

The stock has a market cap of $188.29 million, a PE ratio of -7.12 and a beta of 1.31.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.22 million. Lineage Cell Therapeutics had a negative return on equity of 34.92% and a negative net margin of 295.59%. Equities analysts forecast that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC boosted its stake in Lineage Cell Therapeutics by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock worth $34,000 after purchasing an additional 11,779 shares in the last quarter. DCF Advisers LLC raised its position in shares of Lineage Cell Therapeutics by 14.5% during the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock worth $103,000 after acquiring an additional 12,000 shares during the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in shares of Lineage Cell Therapeutics during the first quarter worth $30,000. Price T Rowe Associates Inc. MD raised its position in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock worth $239,000 after acquiring an additional 70,418 shares during the last quarter. Finally, Comerica Bank raised its position in shares of Lineage Cell Therapeutics by 84,745.8% during the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after acquiring an additional 250,000 shares during the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.